Random mutagenesis in the mouse as a tool in drug discovery.
The flood of raw information generated by large-scale data acquisition technologies in genomics, microarrays and proteomics is changing the early stages of the drug discovery process. Although many more potential drug targets are now available compared with the pre-genomics era, knowledge about the physiological context in which these targets act--information crucial to both discovery and development--is scarce. Random mutagenesis strategies in the mouse provide scalable approaches for both the gene-driven validation of candidate targets in vivo and the discovery of new physiological pathways by phenotype-driven screens.
Russ
Andreas
A
Ingenium Pharmaceuticals, Fraunhoferstrasse 13, D-82152 Martinsried, Germany. andreas.russ@ingenium-ag.com
Stumm
Gabriele
G
Augustin
Martin
M
Sedlmeier
Reinhard
R
Wattler
Sigrid
S
Nehls
Michael
M
D000595:Amino Acid Sequence; D000818:Animals; D004345:Drug Industry / Q000379:methods*; D051379:Mice / Q000235:genetics*; D008969:Molecular Sequence Data; D016296:Mutagenesis / Q000187:drug effects / Q000235:genetics; D015203:Reproducibility of Results; D013678:Technology, Pharmaceutical / Q000379:methods*